Home » Patients » Clinical Studies » Non-Hodgkins
Welcome to Pharmatech Oncology. Below, you will find a clinical study or a list of clinical studies for your primary indication. Please click "Click For Details" to learn about the clinical study and to see if it may be an option for you. Additionally, you may enter your location below to find the closest study center where clinical trials are currently being conducted. If you have any questions, please contact us toll-free at 1-800-383-6610.
Lymphoma, Follicular or Mantle Cell Non-Hodgkins
Study Opportunity

Title: Phase I/II dose escalation study of the Pan-Histone Deacetylase Inhibitor PCI-24781 in Lymphoma
Overview: The first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma. The appropriate dose determined from the first part of the study will be used in the second part of the study to assess disease response in lymphoma patients. Study offers monotherapy every other week to follicular or mantle cell lymphoma patients as second-line treatment for up to 12 cycles or until disease relapse.
Study Value: PCI-24781 is well-tolerated including complete absence of prolonged QTc or other cardiac abnormalities.
Disclaimer: The information presented on this website is not intended to be a substitute for professional medical advice
or to replace your relationship with a physician. For all medical concerns, you should always consult your doctor.
Clinical studies listed are those offered by Pharmatech and do not represent all clinical studies available.